GlassScriptPhysician profile
Amy M Carter
NPI 1821179235
$1,031.16
in general payments reported to CMS, 2019-2025
25 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $52.90 · 2022: $93.23 · 2023: $260 · 2024: $126 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.42 | 2022-2025 | Vraylar |
| Pfizer INC. | $117.45 | 2019-2025 | |
| Lundbeck LLC | $93.80 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $55.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $51.83 | 2019-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $48.33 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $46.01 | 2023-2025 | Ingrezza, Ongentys |
| Medtronic, INC. | $44.33 | 2022-2025 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $38.31 | 2019 | |
| Tactile Systems Technology INC | $29.27 | 2019 | |
| Glaxosmithkline, LLC. | $26.73 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.62 | 2020 | |
| Merck Sharp & Dohme LLC | $21.20 | 2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $21.15 | 2022 | |
| Grifols USA, LLC | $19.87 | 2024 | Prolastin-C Liquid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.95 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.85 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $17.95 | 2025 | Auvelity |
| Astellas Pharma US INC | $16.87 | 2024 | Veozah |
| Allergan, INC. | $16.31 | 2020 | |
| Romark Laboratories, Lc | $15.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $14.59 | 2019 | |
| Mayne Pharma Commercial LLC | $13.77 | 2023 | |
| Phathom Pharmaceuticals, INC. | $9.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.